Status:
RECRUITING
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
Lead Sponsor:
Harbin Medical University
Collaborating Sponsors:
Yangtze River Pharmaceutical Group Co., Ltd.
Conditions:
ST-segment Elevation Myocardial Infarction (STEMI)
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h...
Eligibility Criteria
Inclusion
- the enrolled subjects must meet all of the following criteria:
- Aged 18-75 years old (inclusive);
- Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);
- Sign the informed consent form.
Exclusion
- subjects who meet any one of the following criteria are excluded from the study:
- Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;
- Sinus bradycardia (heart rate sustained \<60 beats/min), PR interval\> 240ms or II-III degree atrioventricular block;
- Continuous systolic blood pressure \<120mmHg;
- Severe breathing difficulties, aterial blood oxygen saturation \<92%;
- Thrombolytic therapy has been performed before the first medical contact in the hospital;
- Consciousness disorder or past cerebrovascular disease;
- Previous history of myocardial infarction or PCI/CABG treatment;
- Known severe liver and kidney dysfunction;
- Known allergy to dexmedetomidine;
- CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;
- Pregnant or lactating women;
- Malignant tumor or expected survival time \<1 year;
- Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and/or follow up);
- Participate in other randomized controlled studies at the same time.
Key Trial Info
Start Date :
May 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04912518
Start Date
May 27 2021
End Date
December 1 2025
Last Update
October 15 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230000
2
The First Affiliated Hospital of Lanzhou University
Lanzhou, Gansu, China, 730000
3
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150000
4
Mudanjiang Cardiovascular Hospital
Mudanjiang, Heilongjiang, China, 1570011